SUVEN

The stock has been placed in Additional Surveillance Measure (ASM) list LTASM - I (13).

Suven Life Sciences Ltd.

NSE: SUVEN

BSE: 530239

Sector: Healthcare

Industry Group: Healthcare Services

Industry: Healthcare Research, Analytics & Technology

317.10-2.2 (-0.70%)

8 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

2.3 / 100

Value Score

2.3 / 100

Price Momentum Score

90.1 / 100

QVM Score

14.5 / 100

Key Metrics

Market Cap

8960.07

P/E (TTM)

P/B

15.15

P/S (TTM)

1259.37

EV/EBITDA

CAPE (5Y)

ROE (TTM)

-78.80

ROCE (TTM)

-80.80

ROA (TTM)

-72.78

Avg 3Y ROE

-65.32

Earnings 3Y CAGR

-22.28

Sales 3Y CAGR

-19.30

Sales 5Y CAGR

-12.00

Debt/Equity

0.03

Consensus TP

Strong Buy %

Promoter Holding

70.15

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Suven Life Sciences Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 90.1 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

90.1 / 100

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.03 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.03 in the last 1 year

What is Debt to Equity?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Stock is fairly expensive with negative EPS on a trailing 12-month basis

Earnings yield of -3.08% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis

What is Earnings yield (E/P)?

Low and declining operating margin

The company reported low operating margin of -4077.7% for 12-month ended 31 Mar 2026 and operating margin declined by -149956 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and in line with median growth of industry

The company delivered low revenue growth of 6.89% for 12-month ended 31 Mar 2026 and the growth was 0.0 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 6.89

Value 6.89

-32.8631.37

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -64.56% for 12-month ended 31 Mar 2026 and the growth was 47.87 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Company's earnings are of low quality

Earnings quality score of 20.2 indicates that the company's earnings are of low quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

20.2 / 100

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Low ROE but improving trend

The company reported low ROE of -78.8% for 12-month ended 31 Mar 2026 but ROE improved by 580 bps from 1 year ago

What is ROE (FY)?

Financial Snapshot

See detailed analysis

Multi-year trends for Suven Life Sciences Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Suven Life Sciences Ltd. Shareholding Pattern

Quarterly breakdown of Suven Life Sciences Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	64.98	64.98	64.98	69.57	69.57	69.57	69.57	69.57	69.57	70.27	70.27	70.27	70.27	70.27	67.36	67.36	70.15
Indian Promoter	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	64.98	64.98	64.98	69.57	69.57	69.57	69.57	69.57	69.57	70.27	70.27	70.27	70.27	70.27	67.36	67.36	70.15
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	4.81	2.35	1.69	1.72	1.14	0.85	0.88	0.96	1.01	0.84	0.60	0.56	0.62	0.56	0.51	0.55	1.51	1.50	1.39	1.39	0.26	0.61	4.57	4.46	5.53
Mutual Funds / UTI	0.37	0.37	0.25	0.25	0.21	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	1.05	1.05	1.05	1.05	0.01	0.01	2.08	2.08	1.79
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	3.95	1.57	1.02	1.05	0.48	0.41	0.44	0.52	0.56	0.45	0.48	0.46	0.51	0.48	0.50	0.54	0.46	0.45	0.33	0.34	0.25	0.58	1.17	1.07	0.91
Other Institutions	0.50	0.42	0.42	0.42	0.45	0.43	0.43	0.43	0.44	0.39	0.11	0.10	0.10	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	1.31	1.31	2.83
Non-Institution	35.19	37.65	38.31	38.28	38.86	39.15	39.12	39.04	34.01	34.18	34.42	29.87	29.81	29.88	29.93	29.89	28.92	28.23	28.34	28.34	29.47	29.13	28.07	28.18	24.32
Bodies Corporate	2.63	2.02	1.20	1.38	1.19	1.40	2.50	2.58	2.39	2.38	2.52	2.49	2.47	2.29	1.23	1.50	2.27	1.90	2.51	2.28	2.27	2.73	2.72	2.77	2.19
Others (incl. Retail) No. of shareholders	32.56 69,162	35.63 74,292	37.11 76,455	36.90 78,208	37.67 77,326	37.75 85,664	36.62 81,111	36.46 79,826	31.62 80,708	31.80 80,681	31.90 79,761	27.38 80,475	27.34 78,296	27.59 75,964	28.70 80,606	28.39 73,693	26.65 68,659	26.33 65,813	25.83 63,618	26.06 63,187	27.20 64,269	26.40 65,760	25.35 64,522	25.41 63,984	22.13 63,535

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	SHI: Biotech	4.01%	9 / 15

Prominent Investor Holdings

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Suven Life Sciences Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Jasti Property and Equity Holdings Private Limited in its capacity as sole trustee of Jasti Family Trust Promoter Group	March-2026	Conversion of security (Acquisition) 10th Mar 2026	65.40 %	₹ 134.00	3.18 cr	₹ 425.70 cr
Jasti Property and Equity Holdings Private Limited in its capacity as sole trustee of the Jasti Family Trust Promoter Group	March-2022	Conversion of security (Acquisition) 29th Mar 2022	60.00 %	₹ 81.57	1.81 cr	₹ 147.64 cr

Corporate Actions

History of Suven Life Sciences Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Rights Issue(1 new shares @ ₹55 for 2 existing shares)
Ex-date: 17th Oct 2022Announced on: 12th Oct 2022
Others
Ex-date: 21st Jan 2020Announced on: 5th Feb 2019
Demerger of suven life sciences limited to Suven pharmaceuticals ltd as Resulting company.The demerged company shall pay each share holding 1 fully paid up equi…
Dividend₹ 1.50/share
Record date: 15th Feb 2019Ex-date: 14th Feb 2019
Announced on: 29th Jan 2019
Dividend₹ 1.50/share
Record date: 7th Feb 2018Ex-date: 6th Feb 2018
Announced on: 19th Jan 2018
Dividend₹ 1/share
Record date: 9th Feb 2017Ex-date: 8th Feb 2017
Announced on: 23rd Jan 2017

Company Profile

Overview of Suven Life Sciences Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Companys lead clinical-stage assets include Masupirdine (...

Key personnel

Mr. M. Mohan Kumar

Chief Financial Officer

Ms. Sangeetha Laxmi Kandari

Company Secretary and Compliance Officer

Shri. Venkateswarlu (Venkat) JastiD

Executive Chairman of the Board, Managing Director

Smt. Sudha Rani JastiD

Wholetime Director

Prof. Dr. Syed E. Hasnain, Ph.D.D

Non-Executive Director

Shri. Santanu MukherjeeD

Independent Non-Executive Director

Smt. J.A.S PadmajaD

Non-Executive Independent Director

Mr. Vajja Sambasiva RaoD

Additional Non-Executive Independent Director

Incorporated on

09 Mar 1989

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

06 Mar 1995

Free Float

7,57,02,687

Website

https://www.suven.com/

Phone no.

+914023541142

Address

DOOR NO. 8-2-334, 6TH FLOOR SDE SERENE CHAMBERS ROAD, NO. 5, AVENUE 7, BANJARA HILLS, , 500034, India

Frequently Asked Questions

What is the current share price of Suven Life Sciences Ltd.?

The current share price of Suven Life Sciences Ltd. is ₹ 317.10 as of 8 Jul 2026.

What is the market capitalisation of Suven Life Sciences Ltd.?

The market capitalisation of Suven Life Sciences Ltd. stands at ₹ 8,960.07 Cr.

What is the PE ratio of Suven Life Sciences Ltd.?

The Price-to-Earnings (PE) ratio of Suven Life Sciences Ltd. is - as of the latest trailing twelve months data.

What is the ROE and ROCE of Suven Life Sciences Ltd.?

Suven Life Sciences Ltd. has a Return on Equity (ROE) of -78.80% and a Return on Capital Employed (ROCE) of -80.80% as per the latest financial reports.

What is the 52-week high and low of Suven Life Sciences Ltd.?

The 52-week high of Suven Life Sciences Ltd. is - and the 52-week low is -.

What is the dividend yield of Suven Life Sciences Ltd.?

The dividend yield of Suven Life Sciences Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Suven Life Sciences Ltd.?

Foreign Institutional Investors (FII) hold 0.91%, Domestic Institutional Investors (DII) hold 1.79% and retail/public investors hold 22.13% of Suven Life Sciences Ltd. shares.

What sector does Suven Life Sciences Ltd. belong to?

Suven Life Sciences Ltd. operates in the Healthcare sector.

What is the beta of Suven Life Sciences Ltd.?

The beta of Suven Life Sciences Ltd. is 1.15, indicating its price volatility relative to the broader market. Over the past 1 year, Suven Life Sciences Ltd. has delivered an absolute return of 29.53%.

What is the RSI of Suven Life Sciences Ltd.?

The 14-day Relative Strength Index (RSI) of Suven Life Sciences Ltd. is 66.85, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Suven Life Sciences Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Suven Life Sciences Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Holdings and Presence

Stock Analysis

Company Profile

Corporate Actions